Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

被引:35
|
作者
Brims, Fraser [1 ,2 ,3 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA 6845, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia
[3] Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia
关键词
mesothelioma; asbestos; epidemiology; pleural disease; TO-LYMPHOCYTE RATIO; PROGNOSTIC-FACTORS; OPEN-LABEL; TALC PLEURODESIS; LUNG-CANCER; SOLUBLE MESOTHELIN; SERUM MESOTHELIN; PHASE-III; DIAGNOSIS; ASBESTOS;
D O I
10.3390/cancers13164194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Prognostic factors in malignant pleural mesothelioma
    Davidson, Ben
    HUMAN PATHOLOGY, 2015, 46 (06) : 789 - 804
  • [22] Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016
    Thomas, Akesh
    Karakattu, Sajin
    Cagle, Jeanette
    Hoskere, Girendra
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [23] Clinical types of thoracic cancer pleural mesothelioma
    Astoul, P.
    REVUE DES MALADIES RESPIRATOIRES, 2006, 23 (05) : S177 - S187
  • [24] A Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma
    Qureshi, Maryum
    Thapa, Bibhusal
    Muruganandan, Sanjeevan
    HEART LUNG AND CIRCULATION, 2023, 32 (05) : 587 - 595
  • [25] Malignant pleural mesothelioma - An update
    Stewart, DJ
    Edwards, JG
    Smythe, WR
    Waller, DA
    O'Byrne, KJ
    INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 2004, 10 (01) : 26 - 39
  • [26] Malignant pleural mesothelioma: current and future perspectives
    Porpodis, Konstantinos
    Zarogoulidis, Paul
    Boutsikou, Efimia
    Papaioannou, Antonis
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Zaric, Bojan
    Perin, Branislav
    Huang, Haidong
    Kougioumtzi, Ioanna
    Spyratos, Dionysios
    Zarogoulidis, Konstantinos
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S397 - S406
  • [27] Imaging of Malignant Pleural Mesothelioma: Pearls and Pitfalls
    Strange, Chad D.
    Shroff, Girish S.
    Ahuja, Jitesh
    Vlahos, Ioannis
    Benveniste, Marcelo F. K.
    Truong, Mylene T.
    SEMINARS IN ULTRASOUND CT AND MRI, 2021, 42 (06) : 542 - 551
  • [28] Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma
    Ripley, R. Taylor
    THORACIC SURGERY CLINICS, 2020, 30 (04) : 451 - +
  • [29] Malignant pleural mesothelioma: A new standard of care
    Stahel, Rolf A.
    LUNG CANCER, 2006, 54 : S9 - S14
  • [30] Pathogenesis of malignant pleural mesothelioma
    Jaurand, MC
    Fleury-Feith, J
    RESPIROLOGY, 2005, 10 (01) : 2 - 8